Atopic Dermatitis

Zalevsky shares insights into the implications of the designation and what it may mean for Rezpeg's development timeline.

Adelaide A. Hebert, MD, FAAD, stressed the importance of educating patients, setting realistic expectations, and ensuring they adhere to AD treatment plans.

Alexandra Golant, MD, led a Dermatology Times Case-Based Roundtable® event that focused on advancing therapeutic strategies for atopic dermatitis.

Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.

At the Horizons in Advanced Practice meeting, Douglas DiRuggiero, DMSc, MHS, PA-C, presented a case of a woman aged 27 years who had eczematous lesions covering more than 20% of her BSA.

New drugs targeting IL-4, IL-13, and IL-31 pathways provide options for tailored eczema treatments.

Lisa Weiss, MMSc, PA-C, and colleagues offered insights on managing severe atopic dermatitis cases with biologics, nonsteroidal treatments, and strategies for addressing physical and emotional impacts.

Panelists discuss how atopic dermatitis is linked to other type 2 inflammatory conditions in the pediatric population, exploring the shared immune pathways and comorbidities that connect these disorders.

Panelists discuss the pathophysiology of atopic dermatitis, highlighting the role of type 2 inflammation in driving the disease process and explaining how this inflammation contributes to the characteristic itch-scratch cycle seen in affected individuals.

The panelist discusses how systemic atopic dermatitis (AD) treatment involves biologics and Janus kinase inhibitors for moderate to severe cases, targeting inflammation and itch with individualized approach based on patient factors, offering significant symptom improvement and skin barrier restoration.

The panelist discusses how atopic dermatitis is a complex chronic skin condition causing significant physical and psychological burden, challenging patients and clinicians through multifaceted management requiring personalized, holistic approaches.

A recent expert discussion highlighted the importance of long-term planning, including when and how to adjust or transition therapies.

Tina Bhutani-Jacques, MD, highlighted the importance of individualized and informative care while building trust among patients and caregivers.

Nektar Therapeutics’ investigational biologic targets the IL-2 receptor complex.

Many patients with severe AD are unaware of newer, more effective treatments.

His presentation at South Beach Symposium will feature Zirwas’ insights on JAK inhibitors, eczema treatments, and emerging therapies.

At the Horizons in Advanced Practice meeting, Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP, presented a case of a woman aged 35 years with widespread eczematous lesions covering over 50% BSA and severe lichenification.

James Del Rosso, DO, explored the treatment landscape and the importance of regular eye exams for patients with AD.

A new review highlights overall allergen rates among children in the United States between 2010 and 2024.

Researchers analyzed stratum corneum hydration and transepidermal water loss across 15 regions of the skin.

According to a systemic review, both topical and oral antifungal therapies are insufficient for managing the disease.

The use of a pre-gel and cleansing lotion regimen saw an improvement rate of 80% for patients with seborrheic dermatitis.

Investigators found strong correlations between certain eating habits, BMI, psychoemotional status, and SD occurrence.

The new partnership will advance the commercialization of small molecule oral STAT6 for patients around the world.

A panelist discusses how recent innovations in topical cream formulations for atopic dermatitis have led to improved efficacy, better tolerability, and enhanced quality of life for patients.